ReviewVaccine2019
Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.
Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 92 citations in OpenAlex.
- Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy.Pharmaceutics · 2026Review
- Global Perspectives on Rabies Prevention and Control: A Decade of World Rabies Day Themes and Progress toward Elimination (2016–2025)Iranian biomedical journal · 2026Review
- Delivery of canine rabies vaccination programme in Kutupalong-Balukhali refugee camps, Cox's Bazar, Bangladesh.PLoS neglected tropical diseases · 2026Article
- Therapeutic Effects of Vernonia amygdalina on Oxidative Stress and Histopathological Damage in Pancreatic Toxicity Induced by 1,2-dimethylhydrazine in Wistar RatsIranian biomedical journal · 2026Article
- Comparative effectiveness and cost-effectiveness of policies for provisioning rabies post-exposure vaccines.Vaccine · 2026Article
- Experiences of piloting integrated bite case management in Zaria Metropolis, Nigeria.Frontiers in tropical diseases · 2026Article
- Temporal changes in rabies epidemiology in Brazil: an analysis of notifications of suspected and confirmed human rabies cases, 2010-2025.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Healthcare accessibility to rabies post-exposure prophylaxis in rural Kenya: implications for vaccine placement and travel time.Frontiers in microbiology · 2026Article
- Drivers of rabies post-exposure prophylaxis noncompletion in Cambodia, 2019 to 2022.PLoS neglected tropical diseases · 2025Article
- Assessing Health System preparedness for dog mediated rabies in South-East Asia Region.Journal of preventive medicine and hygiene · 2025Review
- The Economic Landscape of Global Rabies: A Scoping Review and Future Directions.Tropical medicine and infectious disease · 2025Review
- Availability of anti-rabies vaccine and rabies immunoglobulin in Indian health facilities: a nationwide cross-sectional health facility survey.The Lancet regional health. Southeast Asia · 2025Article
- The Challenge of Lyssavirus Infections in Domestic and Other Animals: A Mix of Virological Confusion, Consternation, Chagrin, and Curiosity.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Assessment of the awareness of rabies, rabies prophylaxis guidelines and rabies practice among physicians in Sudan: a national cross-sectional study, 2024.BMC public health · 2025Article
- Enhancing Human Post-Exposure Rabies Prophylaxis in Canine Rabies Endemic Regions With an Interactive Web Solution.Public health challenges · 2025Article
- Chasing rabies herd immunity: evaluating dog vaccination strategies and post-vaccination survey reliability in urban and peri-urban Bangladesh.Frontiers in microbiology · 2025Article
- Two Decades of Human Rabies in Brazil: Epidemiological Trends, Emerging Risks and Treatment Challenges.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Rabies in rural northeast India: A case report emphasising the urgency of the One Health approach.One health (Amsterdam, Netherlands) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 8 countries.
Funding
Abstract
backgroundRabies is a neglected zoonotic disease with a global burden of approximately 59,000 human deaths a year. Once clinical symptoms appear, rabies is almost invariably fatal; however, with timely and appropriate post-exposure prophylaxis (PEP) consisting of wound washing, vaccine, and in some cases rabies immunoglobulin (RIG), the disease is almost entirely preventable. Access to PEP is limited in many countries, and when available, is often very expensive.
methodsWe distributed a standardized assessment tool electronically to a convenience sample of 25 low- and middle-income countries in Asia and Africa to collect information on rabies PEP procurement, forecasting, distribution, monitoring and reporting. Information was collected from national rabies focal points, focal points at the World Health Organization (WHO) country offices, and others involved in procurement, logistics and distribution of PEP. Because RIG was limited in availability or unavailable in many countries, the assessment focused on vaccine. Data were collected between January 2017 and May 2018.
resultsWe received responses from key informants in 23 countries: 11 countries in Asia and 12 countries in Africa. In 9 of 23 (39%) countries, rabies vaccine was provided for free in the public sector and was consistently available. In 10 (43%) countries, all or some patients were required to pay for the vaccine in the public sector, with the cost of a single dose ranging from US$ 6.60 to US$ 20/dose. The primary reason for the high cost of the vaccine for patients was a lack of funding at the central level to subsidize vaccine costs. In the remaining 4 (17%) countries, vaccine was provided for free but was often unavailable so patients were required to purchase it instead. The majority of countries used the intramuscular route for vaccine administration and only 5 countries exclusively used the dose-sparing intradermal (ID) route. Half (11/22; 50%) of all countries assessed had a standardized distribution system for PEP, separate from the systems used for routine childhood vaccines, and almost half used separate storage facilities at both central and health facility levels. Approximately half (9/22; 41%) of all countries assessed reported having regular weekly, monthly or quarterly reporting on rabies vaccination.
conclusionsWhile all countries in our assessment had rabies vaccines available in the public sector to some extent, barriers to access include the high cost of the vaccine to the government as well as to patients. Countries should be encouraged to use ID administration as this would provide access to rabies vaccine for many more people with the same number of vaccine vials. In addition, standardized monitoring and reporting of vaccine utilization should be encouraged, in order to improve data on PEP needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.